uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. It also develops AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical therapeutic for congestive heart failure; AMT-021, a gene therapy, which has completed Phase I clinical trial for acute intermittent porphyria; AMT-110, a gene therapy that is in Phase I/II clinical trial for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, University of California San Francisco, Bristol-Myers Squibb, and 4D Molecular Therapeutics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
May 2, 2024
RegMed Investors (RMi) Closing Bell: a sigh of relief as sector adds value after earnings releases
May 2, 2024
RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results
May 1, 2024
RegMed Investors (RMi) Closing Bell: the path forward
April 30, 2024
RegMed Investors (RMi) Closing Bell: ending April on a sour note
April 29, 2024
RegMed Investors (RMi) Closing Bell: a month of up, downs; I thought were exercise
April 26, 2024
RegMed Investors (RMi) Closing Bell: I bowed the knee to thank the upside relief
April 25, 2024
RegMed Investors (RMi) Closing Bell: hammered
April 24, 2024
RegMed Investors (RMi) Closing Bell: I told you so
April 23, 2024
RegMed Investors (RMi) Closing Bell: welcoming the upside trend
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors